Gastrointestinal Cancer
Commentary
Local therapies show promise for metastatic lung cancer
Local therapy for colorectal cancer with limited liver-only metastases is now established as a path to potentially excellent long-term survival....
Commentary
The 5-year survival rate for pancreatic cancer is increasing
‘Research is making a difference. And we’re making progress against cancer in general,’ says expert.
From the Journals
Room for improvement in Barrett esophagus care
Researchers say this is the first study to highlight variation in adherence to these measures at the center and endoscopist levels.
Conference Coverage
Long-course radiation therapy better at organ-sparing in rectal cancer than short-term therapy
Patients who underwent short-course therapy had worse organ-preservation outcomes.
Conference Coverage
Colorectal cancer treatment outcomes in older adults
Disease-free survival boosted by adjuvant therapy completion, but only about half of patients finish.
Conference Coverage
Immunotherapy with antibiotics doesn’t worsen biliary tract cancer outcomes
Previous studies and clinical observations have suggested that antibiotics during immunotherapy treatment may hasten negative outcomes.
From the Journals
Physician group issues 31 treatment recommendations for early-onset colorectal cancer
There was strong consensus that all individuals younger than 50 should undergo CRC risk stratification and prompt symptom assessment.
Conference Coverage
New ‘reference regimen’ in metastatic pancreatic cancer?
NALIRIFOX regimen can be considered new reference regimen for first-line pancreatic cancer treatment, a researcher reports at ASCO GI.
Conference Coverage
SUNLIGHT shows new standard of care in refractory metastatic CRC
Adding bevacizumab to trifluridine/tipiracil significantly improved survival, researchers report at ASCO GI.
Conference Coverage
Adding SBRT to sorafenib boosts survival in liver cancer
The use of SBRT in this setting improved both overall survival and progression-free survival, researchers reported at ASCO GI.
Conference Coverage
Regorafenib: New option for advanced gastroesophageal cancer?
Regorafenib significantly improves survival, compared with placebo, in patients with refractory AGOC, researchers report at ASCO GI.